Nasus Pharma Ltd. · AMEX:NSRX
Nasus Pharma — Investor Presentation (November 2025)
31 slides from Nasus Pharma's investor presentation, Nov 3, 2025
Slide 1: A New Frontier in Intranasal Drug Delivery
NASUS ANEW FRONTIER IN INTRANASAL DRUG DELIVERY Aclinical-stage pharmaceutical company - © leveraging its proprietary powder-based intranasal technology to develop innovative intranasal products to treat emergency medical conditions Company Presentation - November 2025 NYSE American
Slide 2: Forward Looking Statements; Disclaimer
Forward Looking Statements; Disclaimer This presentation of Nasus Pharma Ltd. (the “Company”, “Nasus” or “Nasus Pharma”) contains “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995 and other securities law. Words such as “expects,” “intends,” “pla
Slide 3: Company Highlights
Company Highlights Nasus is Uniquely Positioned to Address Medical Emergencies via Intranasal Drug Delivery NS002 was designed to address Proprietary Nasax powder Use of well-known active imines aE CSHS technology aims to enhance pharmaceutical ingredients Epinephrine, with a needle-free, intranasal
Slide 4: Robust Asset Pipeline Setting Up Potential for Long Term Growth
Robust Asset Pipeline Setting Up Potential for Long Term Growth Addressing Significant Medical Emergencies DrugCandidate Molecule Indication Preclinical Phase1 Phase 2 Pivotal Trial Next Milestone Results from Phase 2iepeated dose Epinephrine Anaphylaxis haem ee Q126 Ondansetron Nausea and Vomiting
Slide 5: Proprietary Nasax Platform Enables Superior Drug Absorption
Proprietary Nasax Platform Enables Superior Drug Absorption Powder formulation can reach all parts of nasal cavity; The greater intranasal absorption area enables faster Less surface adhesion Pooling and runoff into nasopharynx Variable droplet size Slower, less predictable absorption Uniform nasal
Slide 6: NS002: Intranasal Epinephrine
NS002: INTRANASAL EPINEPHRINE
Slide 7: Anaphylaxis: A Time-Critical Medical Emergency
Anaphylaxis: A Time-Critical Medical Emergency Anaphylaxis is a severe allergic reaction; fatal in ~1% of cases" The standard of care for anaphylaxis is Epinephrine this is typically self-administered via an Epinephrine auto-injector (EAl) or given via intramuscular (IM) injection by a healthcare pr
Slide 8: Anaphylaxis: A Growing Opportunity in a Large Market
Anaphylaxis: A Growing Opportunity in a Large Market Estimated prevalence of anaphylaxis among the global population’ 9 40M Patients with type 1 allergies in the U.S.° +6.5% From 2010 to 2023 CAGR ED Patients experience severe type | { +12.7%) Global Epinephrine market in 2024? 10, i 3 allergic reac
Slide 9: NS002 Designed to Address the Limitations of Intramuscular Epinephrine
NS002 Designed to Address the Limitations of Intramuscular Epinephrine Autoinjectors' with a 12-18 month shelf-life Large and bulky to carry? Many patients avoid autoinjectors due to a fear of needles? 15cm The proposed solution: NS002 Product candidate aims to offer aneedle-free solution, longer sh
Slide 10: NS002: Completed Milestones
NS002: Completed Milestones Completed NS002/EpiPen single dose PK Phase? study Completed NSO02 pilot study Pro-IND meeting w/ FDA
Slide 11: NS002: Pilot Study Overview
NS002: Pilot Study Overview Study goal: Test NS002’s Epinephrine bioavailability following allergenic challenge PK/PD measurements: plasma Epinepherine, Tmax, T100, AUC, SBP, HR 12 healthy adults with allergic rhinitis (9 male, 3 female) yy Screening: positive to skin allergen test Period 1 Period 2
Slide 12: Pilot Study Results Show NS002 Epinephrine Absorbed into Bloodstream
Pilot Study Results Show NS002 Epinephrine Absorbed into Bloodstream Faster than EpiPen Pilot Study Pharmacokinetics (PK) 700 600 Zs00 Plasma epinephrine — 2 400 —+£piPen 0.3 geometric mean - 60 min. < ~*-Nasus 1.6mg. & —*-Nasus 1.6mgtAllergen challenge = & 300 tAllergs 8 pl : -e-Nasus 3.2me 5 200 -
Slide 13: NS002 Pilot Study Demonstrated Faster and Higher Maximal Epinephrine Absorption Compared to EpiPen
NS002 Pilot Study Demonstrated Faster and Higher Maximal Epinephrine Absorption Compared to EpiPen Pilot study PK - baseline corrected time medians 20.00 z 1500 E tooo 9.00 EE. F500 0.00 EpiPen 50 EpiPen Tmax median (min.) n=12 16.50 | I Nasus 1.6mg _ Nasus 1.ome+Aller challenge T100 pg/mL (minutes)
Slide 14: NS002 PD Results Demonstrated Comparable Epinephrine Activity to EpiPen
NS002 PD Results Demonstrated Comparable Epinephrine Activity to EpiPen Pilot study pharmacodynamics (PD) Systolic Blood Pres: ou - - — Heart Rate N=12 hnieer
Slide 15: NS002: Phase 2 Study Designed to Assess Safety and Tolerability
NS002: Phase 2 Study Designed to Assess Safety and Tolerability, Test Bioavailability, and Optimize Dose for Phase 3 & 1 week 4 1 week A A EpiPen Arm 1: N=6 spray 4.0mg (On each dosing day: in one nostril Screening 12 healthy volunteers, age 18-55 PK sampling: ~1 to 2hr. (13 samples) Plasma Epinephr
Slide 16: Phase 2 Study: More Patients Achieved Hemodynamic Therapeutic Threshold at 6 Minutes
Phase 2 Study: More Patients Achieved Hemodynamic Therapeutic Threshold of Epinephrine by NS002 Compared to EpiPen at 6 Minutes Phase 2 PK results Plasma Epinephrine Results 12 healthy subjects ‘Comparison of Plasma Epinephrine (baseline adjusted) in Healthy Volunteers - Geometric . 380 ‘mean-30min
Slide 17: Phase 2 Study: NS002 Achieves Faster Epinephrine Plasma Concentration than EpiPen
Phase 2 Study: NS002 Achieves Faster Epinephrine Plasma Concentration than EpiPen Mean AUCO-4min #SD n=12 + Mean AUCO-10min +SD N=12 Phase 2 " . ‘ epiren nai 3me in 8.008 PK results Mean AUCO-20min +sp N=12 Mean AUCO-30min +50 n=12 ajar 15489 ; a i] a [ | ed for st wi 2 ere . 17
Slide 18: Phase 2 Study: NS002 Achieves Faster Absorption and Greater Concentration
Phase 2 Study: NS002 Achieves Faster Absorption and Greater Concentration of Epinephrine Compared to EpiPen — Including Time to Hemodynamic Therapeutic Threshold 100pg/ml Phase 2 Results - Cmax, Tmax and T100pg/mL Tmax (median, minutes) N=12 100p¢/mL (median, minutes) N=12 45 2 4 i | | 1 EpiPen Nasu
Slide 19: Phase 2 Study: NS002 Demonstrated Comparable Epinephrine Activity to EpiPen
Phase 2 Study: NS002 Demonstrated Comparable Epinephrine Activity to EpiPen Systolic Blood Pressure n=12 ae Heart Rate N=12 140 Phase 2: 80 PD results =” 20 ° 20 40 60 2 10 © 120 —\£piPen Time (min,) Diastolic Blood Pressure N=12 ts Respistion fige N-12 —Nasus 3.6mg —*Nasus 4.0mg | Pry ° 20 40 60 80
Slide 20: NS002: Phase 2 Results Summary
NS002: Phase 2 Results Summary NS002 Could Be a Compelling Alternative to Epinephrine Autoinjectors NS002 reached the plasma threshold faster than Epi Jowder was well tol ye | give | 04 No findings at nasal examinations No serious adverse events
Slide 21: The Competitive Landscape Indicates a Large and Expanding Opportunity for Needle-Free Epinephrine
The Competitive Landscape Indicates a Large and Expanding Opportunity for Needle-Free Epinephrine PK Parameters ARS Pharma’ Orexo? (Market Cap $885M) (Market CapSEK1.3B) (Market Cap $825M) Neffy (nasal spray) X640 (nasal powder) ANAPHYLM (sublingual) Cmax (Mean) (pg/ml) ‘Tmax (Median) (Minutes) AUC
Slide 22: Progression of Anaphylaxis + Epinephrine Onset of Action
Progression of Anaphylaxis + Epinephrine Onset of Action A Medical Emergency Where Every Second Counts and Speed Matters Nasus FMX1002 ARS-1 Neffy Tmax = 10 min? Tmax = 30 min? > 0 Smin 10min 15min 20min 25min 30min Time of Drug Administration wy OS MiNuTes @ isminutes © 15-30 MINUTES Type 1 Severe
Slide 23: NS002: Clear Roadmap to NDA
NS002: Clear Roadmap to NDA * Following FDA guidance based on the 505b2 regulatory pathway * Demonstration of comparable PK/PD to EpiPen only requirement for regulatory approval * Repeated dose Ph2 study initiates Q4 2025 * Pivotal trial expected to initiate Q3 2026 * Short and cost-effective clinic
Slide 24: NS002: Upcoming Phase 2 Study, Designed to Compare Bioavailability and PK of Repeat Dosing
NS002: Upcoming Phase 2 Study, Designed to Compare Bioavailability and PK of Repeat Dosing 4 Results of the first pre-planned interim analysis expected in Q1 2026 AS 4 @ Group 1 n=25 50 healthy volunteers ‘wallergic rhinitis Age 18-55 On each dosing day: PK sampling: -1 to 2hr. (13 samples) NAsUS PK
Slide 25: NS001: Intranasal Naloxone
NS001: INTRANASAL NALOXONE
Slide 26: Pivotal Study Validated the Superiority of Powder over Liquid
Pivotal Study Validated the Superiority of Powder over Liquid, Demonstrating Nasax Platform Delivers Naloxone Faster Compared to Narcan Mean AUC: 4,10 20 min ‘Mean Plasma ee 20 Mean AUC hag. In our phase 3 (n=42) intranasal naloxone study (NS-001), our formulation provided faster delivery and higher
Slide 27: Robust Patent Portfolio
Robust Patent Portfolio Country Patent No./ Publication No, tDate/ Pub. Date | Status 2/20/2017 Term Ended e/19/2018 | WO20T9/038756Ai National Phase entered arig72038 a/ig/2018 Grant Fee Paid 8/19/2038 8/19/2018 Office Action due: 10/22/2028 9719/2038 a/1g/2018 | CN 110996912 ‘4770/2020 Examination
Slide 28: Proprietary Nasax powder technology designed to enhance intranasal drug absorption
Proprietary Nasax powder technology designed to enhance intranasal drug absorption Lead product candidate NS002 is a needle-free, convenient, easily administered aiming to offer an alternative to Epinephrine autoinjector, directly addressing the currently unmet need Positive Phase 2 data demonstrate
Slide 29: Leadership Team
Leadership Team Udi Gilboa, Co-Founder & Executive Chairman Mr. Giboa sa prominent sera ie sciences entrepreneur and the co-founder of multiplemeicat device and [pharmaceutical companies, He co-founded and served as drectorand CFO of BioBlast Lia (NASDAQ: ORPN), Alcobra Ltd (NASDAQ: ADHD), and insui
Slide 30: A New Frontier in Intranasal Drug Delivery
NASUS ANEW FRONTIER IN INTRANASAL DRUG DELIVERY Aclinical-stage pharmaceutical company - © leveraging its proprietary powder-based intranasal technology to develop innovative intranasal products to treat emergency medical conditions NYSE American
Slide 31: Simplified Supply Chain
Simplified Supply Chain API (Ns002- epinepherine) (NS001 — naloxone) NASUS Nasal powder manufacture a